BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other ...

While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and ...

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to ...

With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with ...

In this episode of Denatured, you'll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, ...

Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity. BioSpace spoke to four industry executives about key issues facing those ...

As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a ...

The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe ...

Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the ...

While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule ...